Biomerica’s inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026
Biomerica announced that an abstract evaluating the real-world clinical effectiveness of its inFoods® IBS diagnostic-guided therapy has been accepted for poster presentation at Digestive Disease Week 2026 in Chicago. The study, conducted by investigators from Michigan Medicine and Cleveland Clinic, builds on previously published trial data showing 59.6% of the treatment group achieved the FDA endpoint for abdominal pain reduction versus 42.1% in the control group.
Key figures
- Tam usd
- $30 billion
- Efficacy ibs c control
- 35.8%
- Efficacy ibs m control
- 29.5%
- Efficacy ibs c treatment
- 67.1%
- Efficacy ibs m treatment
- 66%
- Ibs prevalence adults us
- 30-45 million
- Efficacy abdominal pain control
- 42.1%
- Efficacy abdominal pain treatment
- 59.6%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.